S&P/ASX 200 Index (ASX: XJO) shares are up 1.12% to 8,959.5 points on Tuesday.
Materials is leading the 11 market sectors, up 1.73%, as ASX 200 mining shares continue their strong run.
On The Bull this week, experts revealed their views on three high-profile ASX 200 stocks.
Let's take a look.
BHP Group Ltd (ASX: BHP)
The BHP share price is $49.96, up 3.15% after reaching a two-year high of $50.05 in earlier trading.
Remo Greco from Sanlam Private Wealth has a buy rating on the ASX 200 iron ore giant.
Greco says:
The resources upgrade cycle continues to unfold as global growth conditions strengthen into 2026.
Expected US interest rate cuts should stimulate global growth and put downward pressure on the US dollar.
Commodity markets are already tight in terms of adequate supply, and this is already pushing mining stocks higher.
This is a global theme.
BHP fits the bill as global investors are drawn to earnings upgrades driving share price gains.
Also, investors are exposed to a currency gain if the Australian dollar strengthens during 2026.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is $183.98, up 1.69% on Tuesday.
Pro Medicus stock has plummeted after reaching a record $336 per share in July last year.
Stuart Bromley from Medallion Financial Group has a hold rating on this ASX 200 healthcare share.
Bromley explains:
The company retains best-in-class imaging software that should generate high margins and structural growth from a steady flow of new contract wins amid bigger and longer contract renewals with existing customers.
The significant share price retreat leaves PME as a hold, but also presents an opportunity to enter a top class business at an attractive price.
Myer Holdings Ltd (ASX: MYR)
The Myer share price is steady at 49 cents on Tuesday.
Myer was among the worst-performing ASX stocks of 2025, losing six-tenths of its value to finish at 48 cents per share on 31 December.
Bromley has a sell rating on this ASX 200 consumer retail share.
He explains:
The department store giant delivered disappointing results in full year 2025, in our view.
Sales were weaker than expected. Earnings before interest and tax of $140.3 million, excluding significant items, were down 13.8 per cent on the prior corresponding period. MYR didn't declare a final dividend.
Ongoing cost challenges and pressures on discretionary spending have continued to weigh on investor sentiment.
We see risk/reward skewed towards further downside rather than a stabilised rebound in the current cycle.
